Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Zibelman

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024Robert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
Pageof 6